PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.43%
EBIT growth above 1.5x TRVN's 1.37%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-14.45%
Negative operating income growth while TRVN is at 1.37%. Joel Greenblatt would press for urgent turnaround measures.
43.33%
Net income growth above 1.5x TRVN's 2.76%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
43.35%
EPS growth above 1.5x TRVN's 2.72%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
43.35%
Diluted EPS growth above 1.5x TRVN's 2.72%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.17%
Negative OCF growth while TRVN is at 53.75%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-15.15%
Negative FCF growth while TRVN is at 53.13%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-167027.54%
Negative 10Y OCF/share CAGR while TRVN stands at 19.68%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-35848.35%
Negative 5Y OCF/share CAGR while TRVN is at 19.68%. Joel Greenblatt would question the firm’s operational model or cost structure.
-39776.52%
Negative 3Y OCF/share CAGR while TRVN stands at 19.68%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-711192.96%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-12332.31%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-13057.95%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
90012.37%
10Y equity/share CAGR above 1.5x TRVN's 2154.25%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5373.91%
5Y equity/share CAGR above 1.5x TRVN's 2154.25%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
7310.97%
3Y equity/share CAGR above 1.5x TRVN's 2154.25%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
955.36%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
-33.08%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
0.44%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
34.62%
SG&A growth well above TRVN's 30.38%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.